Arbutus Biopharma Corporation (ABUS)

[DewDiligence]

ABUS 4Q22 results:

https://www.globenewswire.com/news-release/2023/03/02/2619182/14025/en/Arbutus-Reports-Fourth-Quarter-and-Year-End-2022-Financial-Results-and-Corporate-Update.html

We have nominated, AB-343 as our lead coronavirus drug candidate that inhibits the main protease (Mpro). In pre-clinical research conducted thus far, AB-343 has shown pan-coronavirus antiviral activity, no reduction in potency against known SARS-CoV-2 variants, robust activity against SARS-CoV-2 Mpro resistant strains, and a favorable drug-drug interaction profile with no need for ritonavir boosting. We expect to complete IND-enabling studies and initiate a Phase 1 clinical trial with AB-343 in the second half of 2023.

Cash @12/31/22 = $184.3M.